Li Xiuyan, Warren Sophie, Rozenbaum Mark H, Perdrizet Johnna
Global Health Economics and Outcomes Research, Pfizer Inc., New York, NY, USA.
Health Economics and Outcomes Research, Pfizer Inc., Capelle aan den Ijssel, The Netherlands.
Infect Dis Ther. 2023 Mar;12(3):997-1006. doi: 10.1007/s40121-023-00780-7. Epub 2023 Mar 3.
Studies that estimate the economic burden of pediatric pneumococcal disease often only report direct medical costs and omit indirect non-medical costs. Given these indirect costs are not included in most calculations, the full economic burden attributable to pneumococcal conjugate vaccine (PCV) serotypes is often underestimated. This study seeks to quantify the full broader economic burden of pediatric pneumococcal disease associated with PCV serotypes.
We conducted a reanalysis of a previous study where non-medical costs associated with caregiving for a child with pneumococcal disease are considered. The annual indirect non-medical economic burden attributed to PCV serotypes was subsequently calculated for 13 countries. We included five countries with 10-valent (PCV10) national immunization programs (NIPs) (Austria, Finland, The Netherlands, New Zealand, and Sweden) and eight countries with 13-valent (PCV13) NIPs (Australia, Canada, France, Germany, Italy, South Korea, Spain, and the UK). Input parameters were derived from published literature. Indirect costs were inflated to 2021 values in US dollars (USD).
The total annual indirect economic burden associated with pediatric pneumococcal diseases attributable to PCV10, PCV13, the 15-valent (PCV15), and the 20-valent (PCV20) serotypes were $46.51 million, $158.95 million, $223.00 million, and $413.97 million, respectively. The five countries with PCV10 NIPs bear a greater societal burden associated with PCV13 serotypes, whereas the residual societal burden in the eight countries with PCV13 NIPs was primarily attributable to non-PCV13 serotypes.
The inclusion of non-medical costs nearly tripled the total economic burden compared with only including direct medical costs estimated from a previous study. The results from this reanalysis can help inform decision-makers on the broader economic societal burden associated with PCV serotypes and the need for higher-valent PCVs.
估计儿童肺炎球菌疾病经济负担的研究通常仅报告直接医疗成本，而忽略间接非医疗成本。鉴于这些间接成本未包含在大多数计算中，肺炎球菌结合疫苗（PCV）血清型所致的全部经济负担往往被低估。本研究旨在量化与PCV血清型相关的儿童肺炎球菌疾病更广泛的经济负担。
我们对之前一项考虑了肺炎球菌疾病患儿护理相关非医疗成本的研究进行了重新分析。随后计算了13个国家因PCV血清型导致的年度间接非医疗经济负担。我们纳入了5个实施10价（PCV10）国家免疫规划（NIP）的国家（奥地利、芬兰、荷兰、新西兰和瑞典）以及8个实施13价（PCV13）NIP的国家（澳大利亚、加拿大、法国、德国、意大利、韩国、西班牙和英国）。输入参数来自已发表的文献。间接成本按2021年美元价值进行了通胀调整。
PCV10、PCV13、15价（PCV15）和20价（PCV20）血清型所致儿童肺炎球菌疾病的年度间接经济负担总额分别为4651万美元、1.5895亿美元、2.23亿美元和4.1397亿美元。实施PCV10 NIP的5个国家承担了与PCV13血清型相关的更大社会负担，而实施PCV13 NIP的8个国家的剩余社会负担主要归因于非PCV13血清型。
与仅纳入先前研究估计的直接医疗成本相比，纳入非医疗成本使总经济负担增加了近两倍。本次重新分析的结果有助于为决策者提供信息，使其了解与PCV血清型相关的更广泛经济社会负担以及对更高价PCV的需求。
